Inflammation and Autoimmunity

Developing novel treatments for a breadth of inflammatory and autoimmune diseases

Seeking to develop best-in-class and first-in-class treatments for a breadth of inflammatory and autoimmune diseases with unmet medical needs

Leveraging our strength and expertise in immunology science, our research efforts are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease. This approach enables us to identify and select drug targets that have the potential to effectively treat not just one, but multiple inflammatory and autoimmune diseases. Through our advancements in this field, we aim to bring value to the broader scientific community, help redefine standards of care and, ultimately, deliver breakthrough medicines that transform the lives of patients worldwide.

Understanding lupus

Lupus is a complicated autoimmune disease that can have a profound negative impact on a patient’s quality of life. Innovations in lupus therapies have lagged behind compared to other autoimmune diseases. However, recent developments in understanding the underlying biology of the disease and critical pathways are offering new hope.

Understanding the many costs of lupus

Learn more about the burden people with SLE face through indirect costs, including higher levels of unemployment and absenteeism.

The impact of lupus – one patient’s story

Hear more about what it is like to live with this cruel, debilitating disease and how experts in the lupus community believe new, targeted treatments could help.

Interferon science

Type 1 Interferons (IFN) play a critical role in lupus and elevated levels of Type I IFNs are correlated with a more active and severe disease course. The role of the Type I interferon pathway may go beyond lupus; elevated type I IFN gene signature has been found in several other autoimmune diseases. AstraZeneca is investigating how blocking the Type I interferon pathway could lead to new treatment options for interferon-driven disease.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Other (as at 27 April 2017)

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • MEDI9314 atopic dermatitis

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Ppseudomonas aeruginosa pneumonia
  • MEDI4893 prevention of nosocomial Staphylococcus aureus pneumonia
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus
  • lanabecestat (AZD3293) AMARANTH + extension, DAYBREAK-ALZ Early Alzheimer's disease

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)



Veeva-ID: Z4-5352
Date of next review: June 2018